Drug Options for Neuromyelitis Optica
Neuromyelitis Optica (NMO) was previously termed as Devic’s disease and is also termed as Neuromyelitis optica spectrum disorder (NMOSD). It is one of the rarest diseased syndromes of the central Nervous System (CNS), which is an autoimmune disorder wherein the cells of the immune system along with the antibodies has an impact on the spinal cord (myelitis) and optic nerves (optic neuritis). Study done on neuromyelitis optica drug market states the fact that this disease is quite rare, since approximately only 4,000 individuals in the United States have it. The damages that this disease causes to the optic nerve results in inflammation and swelling of the eye leading to pain and vision loss. Moreover, any kind of damage to the spinal cord leads to paralysis or weakened arms and legs, bladder and bowel dysfunction, and loss of sensation. Neuromyelitis optica results in loss of myelin, that is a fatty elements surrounding the nerve fibers and enables nerve signals, and channel from cell to cell. The syndrome has the potential to harm the nerve fibers and put down broken-down tissue. The cause for this condition is generally not known, even though it might seem to occur post an infection, or it may be linked with any other autoimmune condition. Quite often, neuromyelitis optica is diagnosed incorrectly as multiple sclerosis (MS) or comprehended as one of a kind of MS; however NMO is an exclusively distinct condition. This rare condition is known to cause blindness in either one or both the eyes, painful spasms, uncontrollable hiccups and vomiting, etc. The effects of NMO might be reversible in certain cases; nevertheless, it can sometimes be extreme enough to have already caused permanent loss of vision.
Click here to Get free PDF Sample : http://www.marketresearchglobe.com/request-sample/195023
Neuromyelitis Optica Drug Treatment
There is no significant cure for NMO and medicinal drugs have been officially approved to treat it. However, there are several therapies and drugs prescribed to treat the initial attack of this disease.
- Intravenous high dosage of methylprednisolone (corticosteroids)
- Plasma Exchange (PLEX) – in case there is no improvement with corticosteroids, PLEX helps in lowering the level of NMO-IgG in the blood. The PLEX procedure comprises of eliminating the blood from the body with the help of a needle and tubing. The blood plasma is segregated from the blood cells and is substituted with artificial plasma. This entire method lasts for many hours and might be reiterated several times over a spread of few days.
Since the possibility of prevalence is much higher than 90 percent and the effects are usually sever, the continuing treatment to restrain the immune system is necessary. Below mentioned drugs are used for maintaining the therapy:
- rituximab (Rituxan)
- mycophenolate mofetil (CellCept)
- azathioprine (Imuran, Azasan)
Who acquires NMO and when?
As we already know that there are approximately 4,000 people in the United States with NMO and across the world there are a quarter million.
- The disease can occur at any given age; however occurs mostly between the ages 40 and 50.
- It is more women-centric (more than 80 percent) than men
- It can occur in any part of the world and might be the most common form of demyelinating disease in some populations like Asians, Africans, and Native Americans.
List of Tables and Figures
Figure Picture of Neuromyelitis Optica Drug 1
Table Comparison of Main Models from Neuromyelitis Optica Drug Major Manufacturers 2
Table Specification Comparison of Different Types of Neuromyelitis Optica Drug 2
Figure Global Production Market Share of Neuromyelitis Optica Drug by Type in 2015 3
Figure Glucocorticoids Picture 3
Table Major Manufacturers of Glucocorticoids 4
Figure Immunoglobulin Picture 4
Table Major Manufacturers of Immunoglobulin 4
Table Applications of Neuromyelitis Optica Drug 5
Figure 2015 Global Neuromyelitis Optica Drug Major Applications Sales Share 5
Figure Acute attack Examples 6
Table Major Consumers of Acute attack 6
Figure Remission prophylactic treatment Examples 7
Table Major Consumers of Remission prophylactic treatment 7
Figure Industry Chain Structure of Neuromyelitis Optica Drug 8
Table Global Neuromyelitis Optica Drug Major Manufacturers 8
Table Global Major Regions Neuromyelitis Optica Drug Development Status in 2015 9
Table Industry Policy of Neuromyelitis Optica Drug 9
Table Industry News List of Neuromyelitis Optica Drug 10
Table Raw Material Suppliers Analysis 11
Table Equipment Suppliers Analysis 11
Figure 2014 APAC Overview of Average Monthly Labor Cost 12
Figure 2014 Americas Overview of Average Monthly Labor Cost 13
Figure 2014 EMEA Overview of Average Monthly Labor Cost 13
Figure 2010-2015 USA Employment Cost Index (ECI) 14
Figure 2010-2014 China Average Wage of Worker and Growth Rate (CNY/a) 14
Follow Us :
Twitter : https://twitter.com/marketrglobe